Bibliography
- Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997;89(8):2689-700
- Crow AR, Lazarus AH. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfus Med Rev 2008;22(2):103-16
- Kumpel BM. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang 2007;93(2):99-111
- Brinc D, Lazarus AH. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. Hematology Am Soc Hematol Educ Program 2009:185-91
- Brinc D, Denomme GA, Lazarus AH. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models? Curr Opin Hematol 2009;16(6):488-96
- Godeau B, Oksenhendler E, Brossard Y, et al. Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti-D. Transfusion 1996;36(4):328-30
- Atrah HI. Monoclonal anti-D is not effective in the treatment of chronic autoimmune thrombocytopenic purpura. Transfusion 1997;37(4):444; author reply 445-6
- Neppert J, von Witzleben-Schürholz EM. Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti-D: lack of efficiency due to absence of Fc gammaR-inhibiting activity? Transfusion 1997;37(4):444-5; author reply 445-6
- Crow AR, Song S, Semple JW, et al. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol 2001;115(3):679-86
- Song S, Crow AR, Freedman J, Lazarus AH. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 2003;101(9):3708-13
- Song S, Crow AR, Siragam V, et al. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 2005;105(4):1546-8
- Siragam V, Brinc D, Crow AR, et al. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest 2005;115(1):155-60
- Cooper N, Heddle NM, Haas M, et al. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br J Haematol 2004;124(4):511-18
- Easdale S, Stasi R. Rozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaenia. Expert Opin Biol Ther 2013;13(7):1085-92
- Robak T, Windyga J, Trelinski J, et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood 2012;120(18):3670-6
- Cuker A. Are 25 antibodies better than 1? Blood 2012;120(18):3627-8
- Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007;25:21-50
- van de Geijn FE, Wuhrer M, Selman MH, et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res Ther 2009;11(6):R193
- Despotovic JM, Lambert MP, Herman JH, et al. RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME). Transfusion 2012;52(5):1126-36